These limitations alongside the small proportion of patients treated with GLP-1RAs underscores the importance of conducting a prospective trial with predetermined dosing regimens to accurately assess the impact of GLP-1 RAs on lymphedema and to guide future treatment protocols. This evidence concerns the gene GLP1R and lymphedema.